We are monitoring the impact of COVID-19 on Chlamydia Infection Diagnostics and Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 4949
Share on
Share on

Global Chlamydia Infection Diagnostics and Therapeutics Market Size, Share, Trends and Growth Analysis Report – Segmented By Product Type, End User and Region - Industry Size, Share, Growth, Trends, Forecast (2020 to 2025)

Pulished: February, 2020
ID: 4949
Pages: 175

Chlamydia Infection Diagnostics and Therapeutics Market Size (2020 to 2025)

The size of the Global Chlamydia Infection Diagnostics and Therapeutics Market was around USD 2.4 billion in 2020. It is expected to grow at a CAGR of 6.06% to reach USD 3.2 billion by 2025.

Chlamydia is a sexually transmitted disease. The symptoms do not occur early on. It is usually prevalent in areas with poor sanitation. It is the most common STD worldwide. The number of victims has been increasing over the last decade.

MARKET DRIVERS:

Y-O-Y growth in the prevalence and incidence rate of chlamydia infection globally, Y-O-Y growth in the academic research activities, and increasing strategic partnerships between market players and leading research institutes are primarily accelerating the global chlamydia infection diagnostics and therapeutics market.

Additionally, increasing screening coverage and more holistic reporting, particularly in developed countries, higher spending in healthcare in both advanced and emerging economies, availability of sensitive diagnostic tests are other significant factors driving the global chlamydia infection diagnostics therapeutics market. According to the Centre for Disease Control and Prevention, the overall number of chlamydia infection cases confirmed to the CDC in the United States was 1,526,658 in 2015. In other parts of the world, numbers are still at an alarming pace. The rising need for fast and successful diagnostic tests and therapeutics to address this rapidly increasing patient pool is pushing the chlamydia infection diagnostics and therapeutics industry to new heights. Access to and affordability of hypersensitive diagnostic testing are also contributing to the market's growth. 

MARKET RESTRAINTS:

The global demand for chlamydia infection diagnostics and therapeutics is hindered by lack of knowledge of chlamydia diagnostic tests in low and middle-income countries and the stigma associated with voluntary chlamydia screening; the negative societal effect can hamper market development. The most common group for chlamydia infection is those between the ages of 16 and 25, who fear social embarrassment, leading to untreated or undiagnosed chlamydia infections.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2019 to 2025

Base Year

2019

Forecast Period

2020 to 2025

Segments Covered

By Product, End User, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

 

This research report on the global chlamydia infection diagnostics and therapeutics market has been segmented and sub-segmented based on the product, end-user, and region.

Chlamydia Infection Diagnostics and Therapeutics Market – By Product:

  • Diagnostics             
    • Nucleic Acid Amplification Tests (NAATs)
    • Direct Fluorescent Tests
    • PCR
  • Therapeutics          
    • Macrolides
    • Quinolones
    • Sulfonamides
    • Tetracycline
    • Aminopenicillins

Based on product, the NAAT segment is accounted for the largest market share in 2016 and is predicted to grow robustly in the forecast period. It is closely tailed by DFT in terms of CAGR. This is because NAATs are more sensitive and diagnose better. Macrolides are expected to undergo high growth in the forecast period. It also captures the largest market share and is expected to stay at the top in the forecast period.

Chlamydia Infection Diagnostics and Therapeutics Market – By End User:

  • Diagnostics             
    • Hospitals
    • Specialty Clinics
    • Diagnostic Centers
  • Therapeutics          

Chlamydia Infection Diagnostics and Therapeutics Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

North America is the largest regional market, while the Asia Pacific is expected to be the fastest-growing market worldwide. The growth of the North American market is majorly driven by the well-established health-care sector, the chlamydia infection rates, and the provision of well-defined reimbursement policies from public and private health insurance companies. Due in part to proactive public and private sector awareness campaigns, better diagnosis and treatment rates have also resulted in North America capturing the predominant share of the global market.

Due to the emergence of several developing economies and a broad population base, Asia Pacific is another promising market. Generics are the most commonly marketed drugs in the country because the demand is price sensitive. The growth of the Asia Pacific market is expected to expand due to factors such as a wide pool of potential customers, the introduction of government policies aimed at expanding health care coverage, improving facilities, and increasing health care spending.

In Europe, the market is expected to reach the highest CAGR during the forecast period. 

KEY MARKET PARTICIPANTS:

Some of the notable companies leading the global chlamydia infection diagnostics and therapeutics market profiled in this report are Bio-Rad Laboratories, Novartis AG, F Hoffmann-La Roche, Abbott Laboratories, Danaher. Other players in the market include bioMerieux, DiaSorin SpA, Siemens AG, Thermo Fisher Scientific, and Becton Dickinson and Company.

1. Introduction                                

               1.1 Market Definition                    

               1.2 Study Deliverables                  

               1.3 Base Currency, Base Year and Forecast Periods                          

               1.4 General Study Assumptions                 

2. Research Methodology                                          

               2.1 Introduction                             

               2.2 Research Phases                      

                              2.2.1 Secondary Research           

                              2.2.2 Primary Research 

                              2.2.3 Econometric Modelling      

                              2.2.4 Expert Validation  

               2.3 Analysis Design                        

               2.4 Study Timeline                         

3. Overview                                     

               3.1 Executive Summary                

               3.2 Key Inferences                         

               3.3 Epidemology                            

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

               4.1 Market Drivers                         

               4.2 Market Restraints                   

               4.3 Key Challenges                         

               4.4 Current Opportunities in the Market               

5. Market Segmentation                                            

               5.1 Product Type                            

                              5.1.1 Introduction           

                              5.1.2 Diagnostics             

                                             5.1.2.1 Nucleic Acid Amplification Tests (NAATs)

                                             5.1.2.2 Direct Fluorescent Tests

                                             5.1.2.3 PCR

                              5.1.3 Therapeutics          

                                             5.1.3.1 Macrolides

                                             5.1.3.2 Quinolones

                                             5.1.3.3 Sulfonamides

                                             5.1.3.4 Tetracycline

                                             5.1.3.5 Aminopenicillins

                              5.1.4 Y-o-Y Growth Analysis, By Product Type     

                              5.1.5 Market Attractiveness Analysis, By Product Type    

                              5.1.6 Market Share Analysis, By Product Type     

               5.2 End User                     

                              5.2.1 Introduction           

                              5.2.2 Diagnostics             

                                             5.2.2.1 Hospitals

                                             5.2.2.2 Specialty Clinics

                                             5.2.2.3 Diagnostic Centers

                              5.2.3 Therapeutics          

                                             5.2.3.1 Hospital Pharmacies

                                             5.2.3.2 Drugstores

                                             5.2.3.3 Retail Pharmacies

                                             5.2.3.4 Online Pharmacies

                              5.2.4 Y-o-Y Growth Analysis, By End User             

                              5.2.5 Market Attractiveness Analysis, By End User            

                              5.2.6 Market Share Analysis, By End User             

6. Geographical Analysis                                            

               6.1 Introduction                             

                              6.1.1 Regional Trends    

                              6.1.2 Impact Analysis     

                              6.1.3 Y-o-Y Growth Analysis        

                                             6.1.3.1 By Geographical Area

                                             6.1.3.2 By Product Type

                                             6.1.3.3 By End User

                              6.1.4  Market Attractiveness Analysis      

                                             6.1.4.1 By Geographical Area

                                             6.1.4.2 By Product Type

                                             6.1.4.3 By End User

                              6.1.5  Market Share Analysis       

                                             6.1.5.1 By Geographical Area

                                             6.1.5.2 By Product Type

                                             6.1.5.3 By End User

               6.2 North America                         

                              6.1.1 Introduction           

                              6.1.2 United States         

                              6.1.3 Canada     

               6.3 Europe                        

                              6.2.1 Introduction           

                              6.2.2 U.K            

                              6.2.3 Spain         

                              6.2.4 Germany  

                              6.2.5 Italy           

                              6.2.6 France      

               6.4 Asia-Pacific                

                              6.3.1 Introduction           

                              6.3.2 China        

                              6.3.3 India         

                              6.3.4 Japan        

                              6.3.5 Australia   

                              6.3.6 South Korea           

               6.5 Latin America                           

                              6.4.1 Introduction           

                              6.4.2 Brazil         

                              6.4.3 Argentina 

                              6.4.4 Mexico     

                              6.4.5 Rest of Latin America          

               6.6 Middle East & Africa              

                              6.5.1 Introduction           

                              6.5.2 Middle-East           

                              6.5.3 Africa        

7. Strategic Analysis                                      

               7.1 PESTLE analysis                        

                              7.1.1 Political    

                              7.1.2 Economic 

                              7.1.3 Social        

                              7.1.4 Technological        

                              7.1.5 Legal         

                              7.1.6 Environmental       

               7.2 Porter’s Five analysis                             

                              7.2.1 Bargaining Power of Suppliers         

                              7.2.2 Bargaining Power of Consumers     

                              7.2.3 Threat of New Entrants      

                              7.2.4 Threat of Substitute Products and Services

                              7.2.5 Competitive Rivalry within the Industry      

8. Market Leaders' Analysis                                       

               8.1 Bio Rad laboratories               

                              8.1.1 Overview 

                              8.1.2 Product Analysis   

                              8.1.3 Financial analysis  

                              8.1.4 Recent Developments        

                              8.1.5 SWOT analysis       

                              8.1.6 Analyst View          

               8.2 Novartis AG               

               8.3 F Hoffmann-La Roche                           

               8.4 Abbott Laboratories               

               8.5 Danaher                      

               8.6 bioMerieux                

               8.7 DiaSorin SpA                             

               8.8 Siemens AG               

               8.9 Thermo Fisher Scientific                       

               8.10 Becton Dickinson and Company                     

9. Competitive Landscape                                         

               9.1 Market share analysis                           

               9.2 Merger and Acquisition Analysis                       

               9.3 Agreements, collaborations and Joint Ventures                          

               9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                          

               a) List of Tables                

               b) List of Figures                             

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms product type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Chlamydia Infection Diagnostics and Therapeutics Market, By Region, From 2020 to 2025 (USD Billion)
  2. Global Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2020 to 2025 (USD Billion)
  3. Global Diagnostics Market, By Region, From 2020 to 2025 (USD Billion)
  4. Global Therapeutics Market, By Region, From 2020 to 2025 (USD Billion)
  5. Global Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2020 to 2025 (USD Billion)
  6. Global Diagnostics Market, By Region, From 2020 to 2025 (USD Billion)
  7. Global Therapeutics Market, By Region, From 2020 to 2025 (USD Billion)
  8. North America Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2020 to 2025 (USD Billion)
  9. North America Diagnostics Market, By Region, From 2020 to 2025 (USD Billion)
  10. North America Therapeutics Market, By Region, From 2020 to 2025 (USD Billion)
  11. North America Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2020 to 2025 (USD Billion)
  12. North America Diagnostics Market, By Region, From 2020 to 2025 (USD Billion)
  13. North America Therapeutics Market, By Region, From 2020 to 2025 (USD Billion)
  14. United States Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2020 to 2025 (USD Billion)
  15. United States Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2020 to 2025 (USD Billion)
  16. Canada Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2020 to 2025 (USD Billion)
  17. Canada Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2020 to 2025 (USD Billion)
  18. Europe Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2020 to 2025 (USD Billion)
  19. Europe Diagnostics Market, By Region, From 2020 to 2025 (USD Billion)
  20. Europe Therapeutics Market, By Region, From 2020 to 2025 (USD Billion)
  21. Europe Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2020 to 2025 (USD Billion)
  22. Europe Diagnostics Market, By Region, From 2020 to 2025 (USD Billion)
  23. Europe Therapeutics Market, By Region, From 2020 to 2025 (USD Billion)
  24. U.K. Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2020 to 2025 (USD Billion)
  25. U.K. Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2020 to 2025 (USD Billion)
  26. Germany Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2020 to 2025 (USD Billion)
  27. Germany Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2020 to 2025 (USD Billion)
  28. France Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2020 to 2025 (USD Billion)
  29. France Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2020 to 2025 (USD Billion)
  30. Italy Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2020 to 2025 (USD Billion)
  31. Italy Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2020 to 2025 (USD Billion)
  32. Spain Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2020 to 2025 (USD Billion)
  33. Spain Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2020 to 2025 (USD Billion)
  34. Asia Pacific Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2020 to 2025 (USD Billion)
  35. Asia Pacific Diagnostics Market, By Region, From 2020 to 2025 (USD Billion)
  36. Asia Pacific Therapeutics Market, By Region, From 2020 to 2025 (USD Billion)
  37. Asia Pacific Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2020 to 2025 (USD Billion)
  38. Asia Pacific Diagnostics Market, By Region, From 2020 to 2025 (USD Billion)
  39. Asia Pacific Therapeutics Market, By Region, From 2020 to 2025 (USD Billion)
  40. Japan Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2020 to 2025 (USD Billion)
  41. Japan Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2020 to 2025 (USD Billion)
  42. China Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2020 to 2025 (USD Billion)
  43. China Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2020 to 2025 (USD Billion)
  44. India Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2020 to 2025 (USD Billion)
  45. India Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2020 to 2025 (USD Billion)
  46. Australia Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2020 to 2025 (USD Billion)
  47. Australia Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2020 to 2025 (USD Billion)
  48. South Korea Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2020 to 2025 (USD Billion)
  49. South Korea Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2020 to 2025 (USD Billion)
  50. Latin America Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2020 to 2025 (USD Billion)
  51. Latin America Diagnostics Market, By Region, From 2020 to 2025 (USD Billion)
  52. Latin America Therapeutics Market, By Region, From 2020 to 2025 (USD Billion)
  53. Latin America Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2020 to 2025 (USD Billion)
  54. Latin America Diagnostics Market, By Region, From 2020 to 2025 (USD Billion)
  55. Latin America Therapeutics Market, By Region, From 2020 to 2025 (USD Billion)
  56. Brazil Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2020 to 2025 (USD Billion)
  57. Brazil Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2020 to 2025 (USD Billion)
  58. Argentina Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2020 to 2025 (USD Billion)
  59. Argentina Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2020 to 2025 (USD Billion)
  60. Mexico Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2020 to 2025 (USD Billion)
  61. Mexico Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2020 to 2025 (USD Billion)
  62. Rest of Latin America Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2020 to 2025 (USD Billion)
  63. Rest of Latin America Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2020 to 2025 (USD Billion)
  64. Middle East and Africa Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2020 to 2025 (USD Billion)
  65. Middle East and Africa Diagnostics Market, By Region, From 2020 to 2025 (USD Billion)
  66. Middle East and Africa Therapeutics Market, By Region, From 2020 to 2025 (USD Billion)
  67. Middle East and Africa Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2020 to 2025 (USD Billion)
  68. Middle East and Africa Diagnostics Market, By Region, From 2020 to 2025 (USD Billion)
  69. Middle East and Africa Therapeutics Market, By Region, From 2020 to 2025 (USD Billion)
  70. Middle East Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2020 to 2025 (USD Billion)
  71. Middle East Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2020 to 2025 (USD Billion)
  72. Africa Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2020 to 2025 (USD Billion)
  73. Africa Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2020 to 2025 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample